SYNERGY II

• Research type

  Research Study

• Full title

  A Randomized, Double-Blind, Parallel-Group, Active-Controlled, Multi-center Study to Evaluate the Long-Term Safety and Efficacy of Combination of Solifenacin Succinate with Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in Subjects with Overactive Bladder

• IRAS ID

  144552

• Contact name

  Dudley Robinson

• Contact email

  dudley.robinson@nhs.net

• Sponsor organisation

  Astellas Pharma Europe B.V.

• Eudract number

  2012-005736-29

• REC name

  London - Westminster Research Ethics Committee

• REC reference

  14/LO/0124

• Date of REC Opinion

  10 Mar 2014

• REC opinion

  Further Information Favourable Opinion